



## A new total synthesis of pentenomycin

John K. Gallos,\* Katerina C. Damianou and Constantinos C. Dellios

Department of Chemistry, Aristotle University of Thessaloniki, Thessaloniki 540 06, Greece

Received 2 May 2001; revised 12 June 2001; accepted 20 June 2001

**Abstract**—A new total synthesis of enantiomerically pure pentenomycin has been achieved by the intramolecular nitrone cycloaddition of the proper  $\gamma$ -unsaturated aldehyde, easily accessible from L-arabinose, followed by reductive N–O bond cleavage and further oxidative deamination of the resulting aminocyclopentitol. © 2001 Elsevier Science Ltd. All rights reserved.

Pentenomycin antibiotics constitute a family of natural hydroxylated cyclopentanoids, which are produced by *Streptomyces* species and show moderate activity against Gram-positive and Gram-negative bacteria.<sup>1,2</sup> Among them, pentenomycin I **1**, usually referred to simply as pentenomycin, has attracted considerable attention and a number of syntheses of racemic and enantiopure material have been reported.<sup>2</sup> We now wish to report an efficient synthesis of enantiomerically pure pentenomycin, starting from the naturally abundant L-arabinose. The crucial step of formation of the five-membered ring involves an intramolecular nitrone cycloaddition, a reaction we had applied some time ago<sup>3</sup> to the synthesis of aminocyclopentitols **4** from the unsaturated aldehyde **2**, via the adduct **3** (Fig. 1).

In order to construct the two chiral centres of pentenomycin with the correct absolute configuration, we started from L-arabinose, which was readily converted to the protected L-erythrose **5** (Scheme 1).<sup>4</sup> The hydroxymethyl group was introduced by treatment of **5** with CH<sub>2</sub>O in the presence of K<sub>2</sub>CO<sub>3</sub> according to the literature<sup>5</sup> and subsequently was tritylated by standard procedures.<sup>6</sup> Wittig olefination of **6** with Ph<sub>3</sub>P=CH<sub>2</sub> yielded the alcohol **7**, which was then subjected to

Swern oxidation, condensation with MeNHOH and reflux of the resulting nitrone in chlorobenzene<sup>3</sup> to give in good overall yield the bicyclic oxazine **8**, together with its diastereomeric adduct in a ratio of ca. 8:1 (the major isomer shown hereafter in Scheme 1). Since both diastereoisomers give the same final product, they were used further as a mixture, although they are easily separable chromatographically.<sup>7,8</sup>

The best conditions found for the N–O bond cleavage were hydrogenolysis with H<sub>2</sub> over Pd(OH)<sub>2</sub> in MeOH; the aminocyclitol **9** formed was methylated with an excess of MeI to afford the ammonium salt **10a**, expected to give the desired protected pentenomycin **11b** upon oxidation of the unprotected hydroxyl group and spontaneous elimination of the ammonium group.<sup>9</sup> Swern oxidation, however, gave the detritylated **11b** in low yield, whereas oxidation with PDC afforded the iodinated compound **11a** in quantitative yield (98%). Evidently, the PDC oxidises iodide to molecular iodine, which in the presence of pyridine (from PDC) iodinates the enone already formed.<sup>10</sup> Repeated washing of **10a** with aqueous NaCl caused partial replacement of iodide by chloride and further PDC oxidation gave the desired **11b** (42%) together with **11a** (32%). Much more





Figure 1.

\* Corresponding author. Fax: ++31-997679; e-mail: igallos@chem.auth.gr



**Scheme 1.** Reagents and conditions: (i)  $\text{CH}_2\text{O}$ ,  $\text{K}_2\text{CO}_3$ , MeOH, reflux, 3 days, 82%; (ii)  $\text{Ph}_3\text{C-Cl}$ , pyridine (dry),  $60^\circ\text{C}$ , 2 days, 59%; (iii)  $\text{Ph}_3\text{P}^+\text{CH}_3\text{Br}^-$ , 12-crown-4, *n*-BuLi, THF,  $-70 \rightarrow 0^\circ\text{C}$ , 98%; (iv)  $(\text{COCl})_2$ , DMSO,  $\text{Et}_3\text{N}$ ,  $\text{CH}_2\text{Cl}_2$ ,  $-50$  to  $20^\circ\text{C}$ , 30 min; (v) MeNHOH·HCl,  $\text{Na}_2\text{CO}_3$ , EtOH,  $20^\circ\text{C}$ , 15 min; (vi) PhCl, reflux, 15 min, 53% from **7**; (vii)  $\text{Pd}(\text{OH})_2/\text{C}$ ,  $\text{H}_2$ , MeOH,  $20^\circ\text{C}$ , 15 h, 52%; (viii) MeI,  $\text{K}_2\text{CO}_3$ , THF,  $20^\circ\text{C}$  or MeOTs,  $\text{K}_2\text{CO}_3$ , THF, reflux; (ix) PDC,  $\text{CH}_2\text{Cl}_2$ ,  $20^\circ\text{C}$ , 2 h, 66% of **11b** from **9** via **10b**; (x) aqueous HCl 1N, THF,  $20^\circ\text{C}$ , 12 h, 90%.

satisfactory results were obtained when the quaternisation of amine **9** was attempted with methyl *p*-toluenesulfonate. The resulting trimethylammonium *p*-toluenesulfonate **10b** was smoothly oxidised with PDC to give **11b** in 66% yield from **9**. Deprotection of **11b** with 1N aqueous HCl in THF gave pentenomycin **1** in 90% yield, with spectroscopic and physical data identical to those reported in the literature.<sup>2</sup>

In short, we have developed a new synthesis of enantiopure pentenomycin, utilising cheap and easily available materials, applying simple and convenient methods. The methodology used could be developed as a new general synthesis of chiral cyclopentenones, the scope and limitation of which is under consideration. In addition, the aminocyclopentitols intermediates such as **9** are also of considerable importance as glycosidase inhibitors and carbocyclic nucleoside precursors.<sup>11</sup>

## References

- (a) Umino, K.; Furama, T.; Matzuzawa, N.; Awataguchi, Y.; Ito, Y.; Okuda, T. *J. Antibiot.* **1973**, *26*, 506–512; (b) Umino, K.; Takeda, N.; Ito, Y.; Okuda, T. *Chem. Pharm. Bull.* **1974**, *22*, 1233–1238.
- Selected publications: (a) Smith, III, A. B.; Branca, S. J.; Pilla, N. N.; Guaciaro, M. A. *J. Org. Chem.* **1982**, *47*, 1855–1869; (b) Verlaak, J. M. J.; Klunder, A. J. H.; Zwanenburg, B. *Tetrahedron Lett.* **1982**, *23*, 5463–5466; (c) Hetmanski, M.; Purcell, N.; Stoodley, R. J.; Palfreyman, M. N. *J. Chem. Soc., Perkin Trans. 1* **1984**, 2089–2096; (d) Johnson, C. R.; Barbachyn, M. R. *J. Am. Chem. Soc.* **1984**, *106*, 2459–2461; (e) Achab, S.; Cosson, J.-P.; Das, B. C. *J. Chem. Soc., Chem. Commun.* **1984**, 1040–1041; (f) Pohmakotr, M.; Popuang, S.; *Tetrahedron Lett.* **1991**, *32*, 275–278; (g) Sugahara, T.; Ogasawara, K. *Synlett* **1999**, 419–420; (h) Seepersaud, M.; Al-Abed, Y. *Tetrahedron Lett.* **2000**, *41*, 4291–4293.
- Gallos, J. K.; Goga, E. G.; Koumbis, A. E. *J. Chem. Soc., Perkin Trans. 1* **1994**, 613–614.
- (a) Thompson, D. K.; Hubert, C. N.; Wightman, R. H. *Tetrahedron* **1993**, *49*, 3827–3840; (b) Hall, A.; Meldrum, K. P.; Therond, P. R.; Wightman, R. H. *Synlett* **1997**, 123–125; (c) Gallos, J. K.; Dellios, C. C.; Spata, E. E. *Eur. J. Org. Chem.* **2001**, 79–82.
- (a) Bols, M. *Carbohydrate Building Blocks*; John Wiley & Sons: New York, 1996; (b) Ho, P.-T. *Tetrahedron Lett.* **1978**, *19*, 1623–1626.
- (a) Greene, T. W.; Wuts, P. G. M. *Protective Groups in Organic Synthesis*, 2nd ed., John Wiley & Sons: New York, 1991; (b) Kocienski, P. J. *Protecting Groups*; Georg Thieme Verlag: Stuttgart, 1994.
- All new compounds gave spectral and analytical data consistent with the proposed structures. Selected NMR and physical data are listed. Compound **7**: oil,  $[\alpha]_D -11.9$  (*c* 1.15,  $\text{CHCl}_3$ );  $^1\text{H NMR}$  ( $\text{CDCl}_3$ )  $\delta$  1.33 (s, 3H), 1.49 (s, 3H), 3.18 (d, 1H,  $J=9.0$  Hz), 3.27 (d, 1H,  $J=9.0$  Hz), 3.65 (two dd as m, 2H), 4.12 (dd, 1H,  $J=7.0$ , 4.7 Hz), 5.24 (dd, 1H,  $J=10.6$ , 2.2 Hz), 5.45 (dd, 1H,  $J=17.2$ , 2.2 Hz), 5.93 (dd, 1H,  $J=17.2$ , 10.6 Hz), 7.25 (m, 9H), 7.35 (m, 6H);  $^{13}\text{C NMR}$  ( $\text{CDCl}_3$ )  $\delta$  26.5, 27.9, 62.4, 68.1, 81.5, 83.3, 87.3, 109.0, 116.2, 127.1, 127.9, 128.7, 135.9, 143.4; HRMS (MALDI-FTMS) calcd ( $\text{C}_{28}\text{H}_{30}\text{O}_4\text{Na}$ ) 453.2036 (M+Na), found 453.2037,  $\sigma$  0.2 ppm. Compound **8**: oil,  $[\alpha]_D -7.5$  (*c* 1.29,  $\text{CHCl}_3$ );  $^1\text{H NMR}$  ( $\text{CDCl}_3$ )  $\delta$  1.07 (s, 3H), 1.44 (s, 3H), 1.98 (d, 1H,  $J=11.1$  Hz), 2.17 (d, 1H,  $J=11.1$  Hz), 2.56 (s, 3H), 3.30 (s, 1H), 3.34 (d, 1H,  $J=9.7$  Hz), 3.41 (d, 1H,  $J=9.7$  Hz), 3.75 (s, 1H), 4.72 (s, 1H), 7.27 (m, 9H), 7.52 (m, 6H);  $^{13}\text{C NMR}$  ( $\text{CDCl}_3$ )  $\delta$  26.4, 27.0, 28.7, 45.2, 64.3, 65.9, 77.4, 81.2, 86.5, 89.4, 111.6, 126.8, 127.6, 128.9, 144.1; HRMS (MALDI-FTMS) calcd ( $\text{C}_{29}\text{H}_{31}\text{NO}_4\text{Na}$ ) 480.2145 (M+Na), found 480.2159,  $\sigma$  2.9 ppm. Compound **9**: oil,  $[\alpha]_D -30.8$  (*c* 0.33,  $\text{CHCl}_3$ );  $^1\text{H NMR}$  ( $\text{CDCl}_3$ )  $\delta$  1.14 (s, 3H), 1.40 (s, 3H), 1.79 (d, 1H,  $J=14.2$  Hz), 2.20 (dt, 1H,  $J=14.2$ , 4.4 Hz), 2.30 (br s, 2H, OH, NH), 2.36 (s, 3H), 3.05 (d, 1H,

- $J=4.4$  Hz), 3.40 (d, 1H,  $J=9.8$  Hz), 3.69 (d, 1H,  $J=9.8$  Hz), 4.13 (s, 1H), 4.20 (d, 1H,  $J=4.4$  Hz), 7.28 (m, 9H), 7.54 (m, 6H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  26.7, 27.9, 34.2, 35.1, 65.4, 66.7, 79.4, 85.8, 87.2, 94.2, 110.9, 127.0, 127.8, 128.8, 143.8; HRMS (MALDI-FTMS) calcd ( $\text{C}_{29}\text{H}_{33}\text{NO}_4\text{Na}$ ) 482.2302 (M+Na), found 482.2301,  $\sigma$  0.2 ppm. Compound **11b**: oil,  $[\alpha]_{\text{D}}^{25} +15.7$  ( $c$  0.5,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.31 (s, 3H), 1.34 (s, 3H), 3.29 (d, 1H,  $J$  8.8 Hz), 3.48 (d, 1H,  $J=8.8$  Hz), 5.05 (d, 1H,  $J=2.0$  Hz), 6.28 (d, 1H,  $J=5.9$  Hz), 7.25 (m, 15H), 7.66 (dd, 1H,  $J=5.9$ , 2.0 Hz);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  28.4, 28.6, 62.6, 82.1, 83.8, 87.1, 115.3, 127.2, 127.9, 128.7, 134.9, 143.3, 160.1, 204.3; HRMS (MALDI-FTMS) calcd ( $\text{C}_{28}\text{H}_{26}\text{O}_4\text{Na}$ ) 449.1723 (M+Na), found 449.1729,  $\sigma$  1.3 ppm.
8. The absolute configuration of the newly formed stereocentres in the major isomer of cycloadduct **8** (and therefore for **9** and **10**) was deduced from NOE experiments. The significant signal enhancement of the *endo*-Me of the acetonide group ( $\delta$  1.44) when irradiating the *endo*-H of the bridged methylene group ( $\delta$  2.17) is mostly characteristic and leaves little doubt on the structure of **8**.
9. (a) Jiang, S.; Mekki, B.; Singh, G.; Wightman, R. H. *Tetrahedron Lett.* **1994**, *35*, 5505–5508; (b) van Boggelen, M. P.; van Dommelen, B. F. G. A.; Jiang, S.; Singh, G. *Tetrahedron Lett.* **1995**, *36*, 1899–1902; (c) Jiang, S.; Mekki, B.; McCoullouth, K. J.; Singh, G.; Wightman, R. H. *J. Chem. Soc., Perkin Trans. 1* **1997**, 1805–1814.
10. Johnson, C. R.; Adams, J. P.; Braun, M. P.; Senanayake, C. B. W.; Uskoković, M. R.; Wovkulich, P. M. *Tetrahedron Lett.* **1992**, *33*, 917–918.
11. (a) Berecibar, A.; Grandjean, C.; Siriwardena, A. *Chem. Rev.* **1999**, *99*, 779–844; (b) Crimmins, M. T. *Tetrahedron* **1998**, *54*, 9229–9272.